United Therapeutics Co. (NASDAQ:UTHR) Director Sells $980,532.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $272.37, for a total transaction of $980,532.00. Following the completion of the transaction, the director now directly owns 130 shares of the company's stock, valued at approximately $35,408.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Trading Up 0.1 %

UTHR traded up $0.41 during trading on Monday, hitting $274.67. 333,292 shares of the stock traded hands, compared to its average volume of 460,013. The firm has a market capitalization of $12.18 billion, a P/E ratio of 12.99 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The firm has a 50-day moving average of $244.51 and a 200 day moving average of $232.72. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $275.42.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.86 EPS. Equities research analysts anticipate that United Therapeutics Co. will post 24.2 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its position in United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company's stock valued at $1,982,000 after buying an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale lifted its position in shares of United Therapeutics by 54.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company's stock worth $20,617,000 after purchasing an additional 33,338 shares during the period. Nordea Investment Management AB lifted its position in shares of United Therapeutics by 155.2% in the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company's stock worth $8,427,000 after purchasing an additional 23,532 shares during the period. BNP Paribas Financial Markets lifted its position in shares of United Therapeutics by 90.3% in the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company's stock worth $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Duality Advisers LP lifted its position in shares of United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company's stock worth $3,440,000 after purchasing an additional 5,622 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on UTHR shares. Oppenheimer boosted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an "outperform" rating in a research note on Thursday, May 2nd. HC Wainwright reissued a "buy" rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. SVB Leerink began coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an "outperform" rating and a $330.00 price target for the company. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, Wells Fargo & Company upped their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.